Reacting to skyrocketing prices for insulin, the Trump Administration announced on Tuesday a new benefit that would limit Medicare recipients’ copays for insulin to a maximum of $35 a month and save them about $446 a year if they have prescription plans that offer the benefit.
In-hospital use of continuous glucose monitoring may offer improvements in glycemic control and reduced exposure to COVID-19 for healthcare professionals.
Careful consideration should be taken before using hydroxychloroquine in patients with diabetes, particularly in the context of COVID-19.
The first guidelines for assessing the eligibility of patients with NASH for inclusion in clinical studies were released.
The reduction in left ventricular mass observed in patients with stable coronary artery disease and type 2 diabetes treated with empagliflozin may not result of an effect of this drug on diastolic function.
In Mendelian randomization analyses, obesity was not causatively linked to either benign nodular thyroid disease or thyroid cancer.
Experts proposed new guidelines on the diagnosis of metabolic-associated fatty liver disease (MAFLD), formerly non-alcohol fatty liver disease (NAFLD).
Large adult body size contributes to the association between genetically predicted larger body size in childhood and coronary artery disease and type 2 diabetes later in life.
Results from the phase 3 AWARD-11 trial evaluating higher doses of dulaglutide showed superior HbA1c and body weight reductions with an investigational 4.5mg dose in patients with type 2 diabetes (T2D) compared with dulaglutide 1.5mg.
Prediabetes is not associated with cognition after stroke, whereas type 2 diabetes increases the risk for lower poststroke cognitive function.